Loading...

VRDN VIRIDIAN THERAPEUTICS INC Expansion Plans 8-K Filing

VRDN

VRDN

VIRIDIAN THERAPEUTICS INC

(VRDN)

2026 8-K

Convertible Notes Offering

Financial Update

Clinical Trial Results

Financial Results Report

Financial Results Report

Stock Offering Announcement

Cash Position Update

New Funding Agreement

Financial Statements

Financial Statements

Director Appointment

Stock Sale Agreement

Financial Results

CFO Appointment

Positive Trial Results

Financial Results

Positive Trial Results

Financial Results

Investor Presentation

Annual Meeting Approval

Financial Results

Lease Agreement Amendment

Financial Results

Underwriting Agreement

Departure and Appointment o...

Financial Results

Resignation and Bylaws Adop...

Private Placement and Manag...

Appointment of Director

Management Change

Regulation FD Disclosure

Annual Meeting Approval

Financial Results

Departure of Directors

Regulation FD Disclosure

Financial Results

Appointment of President an...

External Links:

On May 5, 2026, Viridian Therapeutics, Inc. reported topline data from its phase 3 REVEAL-2 clinical trial for elegrobart, an antibody for chronic thyroid eye disease. This filing is significant for investors as it may impact the company's future prospects.

AI Assistant

VIRIDIAN THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.